10-Tage Monotherapie mit Bictegravir bei HIV-Infizierten

Zurück zur Übersicht

16.-20.06.2016 / ASM Microbe / Boston, MA, USA

    Novel Integrase Strand Transfer Inhibitor Bictegravir 10 Day Monotherapy in HIV-1–Infected Patients

    by J Gallant, M Thompson, E DeJesus, G Voskuhl, X Wei, J Zack, K White, H Martin, J Szwarcberg

    Integrase strand transfer inhibitors (INSTIs) are a recommended class of antiretrovirals (ARVs) for treatment of HIV-1 in treatment guidelines

    • Three INSTIs are currently approved: raltegravir (RAL), elvitegravir (EVG), and dolutegravir (DTG)
      • RAL requires twice-daily administration, and EVG requires pharmaco-enhancement for once-daily dosing, which creates more potential drug-drug interactions
      • RAL and EVG have overlapping resistance profiles
      • DTG is an unboosted INSTI that can be administered once daily
      • While DTG retains activity against most RAL- and EVG-resistant variants, it must be dosed twice daily in patients with known or suspected INSTI resistance, or when coadministered with cytochrome P450 or uridine diphosphate glucuronosyltransferase inducers
    • Bictegravir (BIC; GS-9883) is a novel, potent, once-daily, unboosted INSTI with in vitro activity against most INSTI resistant variants
    • BIC is currently in clinical development in combination with tenofovir alafenamide and emtricitabine as a single-tablet regimen for the treatment of HIV-1 infection

    Studiensammlung zu HIV

    Zur Übersicht